IRIS
NECCHI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.223
AS - Asia 6.728
NA - Nord America 4.111
SA - Sud America 2.206
AF - Africa 167
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 10
Totale 20.460
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 4.298
US - Stati Uniti d'America 3.871
SG - Singapore 2.562
BR - Brasile 1.808
CN - Cina 1.771
HK - Hong Kong 1.082
SE - Svezia 917
VN - Vietnam 697
IT - Italia 397
DE - Germania 356
FR - Francia 349
RO - Romania 267
AR - Argentina 155
IN - India 154
GB - Regno Unito 133
FI - Finlandia 121
AT - Austria 109
CA - Canada 106
BD - Bangladesh 90
MX - Messico 85
PL - Polonia 61
IQ - Iraq 60
ZA - Sudafrica 57
EC - Ecuador 54
ID - Indonesia 53
NL - Olanda 53
JP - Giappone 51
ES - Italia 43
CO - Colombia 42
IE - Irlanda 36
TR - Turchia 36
VE - Venezuela 34
PY - Paraguay 33
CL - Cile 31
UA - Ucraina 25
PK - Pakistan 24
MA - Marocco 22
TN - Tunisia 22
PE - Perù 20
UY - Uruguay 18
UZ - Uzbekistan 17
EG - Egitto 15
SA - Arabia Saudita 15
AU - Australia 13
KE - Kenya 13
LT - Lituania 13
AZ - Azerbaigian 10
IR - Iran 10
DO - Repubblica Dominicana 9
JM - Giamaica 9
PH - Filippine 9
EU - Europa 8
JO - Giordania 8
NI - Nicaragua 8
NP - Nepal 8
SN - Senegal 8
AE - Emirati Arabi Uniti 7
DZ - Algeria 7
LB - Libano 7
MY - Malesia 7
NG - Nigeria 7
BE - Belgio 6
BH - Bahrain 6
BO - Bolivia 6
KW - Kuwait 6
KZ - Kazakistan 6
BG - Bulgaria 5
IL - Israele 5
PA - Panama 5
AL - Albania 4
CI - Costa d'Avorio 4
KR - Corea 4
PR - Porto Rico 4
PT - Portogallo 4
BA - Bosnia-Erzegovina 3
BB - Barbados 3
BN - Brunei Darussalam 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
GR - Grecia 3
GY - Guiana 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
LY - Libia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
BY - Bielorussia 2
CH - Svizzera 2
CY - Cipro 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
MD - Moldavia 2
QA - Qatar 2
SR - Suriname 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
Totale 20.442
Salva come PNG Salva come JPEG
Città #
Singapore 1.194
Hong Kong 1.078
Moscow 950
Ashburn 607
Dallas 564
Shanghai 423
San Jose 372
Hefei 345
Lawrence 302
Princeton 302
Lauterbourg 288
Ho Chi Minh City 285
Beijing 208
New York 189
São Paulo 165
Hanoi 150
Los Angeles 122
Nuremberg 113
Milan 108
Boardman 96
Helsinki 70
Rio de Janeiro 66
Munich 61
Santa Clara 55
Orem 52
Rome 50
Warsaw 44
Tokyo 43
Montreal 42
Vienna 41
Belo Horizonte 37
Frankfurt am Main 36
Turku 36
Brasília 35
Dublin 34
Da Nang 33
Chennai 31
Haiphong 31
Brooklyn 30
Denver 28
Mexico City 26
Phoenix 26
Poplar 26
Porto Alegre 26
Guangzhou 24
Houston 24
Johannesburg 24
Campinas 23
Mumbai 23
Salvador 23
Atlanta 22
London 22
Pune 22
Chicago 21
Toronto 21
Curitiba 20
Stockholm 20
Amsterdam 19
Council Bluffs 19
Biên Hòa 18
Turin 18
Caxias do Sul 17
Erbil 17
Manchester 17
Recife 16
Tashkent 16
Baghdad 15
Bogotá 15
Columbus 15
Dhaka 15
Hải Dương 15
Sorocaba 15
Fortaleza 14
Guayaquil 14
Kassel 14
Lappeenranta 14
Manaus 14
Montevideo 14
Quito 14
Seattle 14
Ankara 13
Buenos Aires 13
Charlotte 13
Guarulhos 13
Ribeirão Preto 13
The Dalles 13
Tianjin 13
Washington 13
Asunción 12
Goiânia 12
Lima 12
Nairobi 12
Osasco 12
Santo André 12
Thái Bình 12
Thái Nguyên 12
Can Tho 11
Caracas 11
Carapicuíba 11
Querétaro 11
Totale 9.712
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 373
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 205
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy––A large, retrospective, single-center study 162
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 155
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard 134
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis 133
A global approach to improving penile cancer care 130
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis 130
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 126
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer 124
A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings 122
Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma 121
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review 119
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? 118
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma 117
Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy 117
Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy 116
A risk calculator predicting recurrence in lymph node metastatic penile cancer 115
Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence 113
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 113
Pulmonary lesion after surgery for renal cancer: progression or new primary? 112
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma 110
Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation 109
Causal contributors to tissue stiffness and clinical relevance in urology 109
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 108
Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients 107
Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration 106
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 106
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis 103
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies 102
Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus 102
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial 101
ASSOCIATION BETWEEN BRCA 1/2 POLYMORPHISMS AND DISEASE AGGRESSIVENESS IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 101
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy 100
[The treatment of early-stage germ cell tumors of the testis (GCTT)]. [Il trattamento dei Tumori Germinali del Testicolo (TGT) in fase iniziale.] 99
ASSOCIATION BETWEEN POLYMORPHISMS OF HOMOLOGOUS RECOMBINATION RAD51B AND DISEASE RECURRENCE IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 97
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study 97
Von Hippel-Lindau disease-associated renal cell carcinoma: a call to action 95
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial 95
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints 95
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies 94
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? 94
Multidisciplinary management of patients diagnosed with von Hippel-Lindau disease: A practical review of the literature for clinicians 93
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor beta (TGF beta) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial 93
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma 93
Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41 93
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study 93
Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study 92
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 92
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer 91
High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? 88
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer 87
Evaluation of cognitive function in trials testing new-generation hormonal therapy in patients with prostate cancer: A systematic review 86
The obesity paradox in metastatic castration-resistant prostate cancer 86
Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration 85
A Plea for Economically Sustainable Evidence-based Guidelines 85
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? 83
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial 82
Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities 82
Topographic modification of the extracellular matrix precedes the onset of bladder cancer 81
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma 81
Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer 81
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression 79
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study 79
Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent 78
Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer 78
Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial 78
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty 77
Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients 76
Adjuvant Therapy in Nonmetastatic High-risk Kidney Cancer: Importance of the Timing of Postnephrectomy Imaging and Treatment Delivery 75
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure 75
Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database 74
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis 73
Penile cancer 73
Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology–Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration 72
A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center 72
A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors 72
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy? 72
Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database 71
Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy 69
Penile cancer 69
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma 68
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma 68
The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial 67
Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage i nonseminomatous germ cell tumours: Long-term outcome and analysis of risk factors of recurrence 67
Targetable gene fusions and aberrations in genitourinary oncology 67
Immune-based therapies in penile cancer 66
EARLY AND LATE HEAT-SHOCK PROTEINS IN WHEATS AND OTHER CEREAL SPECIES 66
Teratoma With Somatic-Type Malignant Components in Germ Cell Tumors of the Testis: A Clinicopathologic Analysis of 40 Cases With Outcome Correlation 66
Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma 66
The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification 66
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center 65
Neoadjuvant chemotherapy for lymph node-positive penile cancer: Current evidence and knowledge 65
Revolutionizing care for rare genitourinary tumours 65
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial 64
Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review 64
Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research 63
Funcion sparing surgery in uro-oncology: germ cell tumors of the testis [La chirurgia "function sparing" in urologia oncologica: tumori germinali del testicolo (TGT)] 62
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer 62
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis 61
Totale 9.482
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.872
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.872
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022270 0 53 3 101 1 8 13 10 13 11 4 53
2022/20231.668 675 354 123 38 18 233 47 94 48 5 15 18
2023/2024934 23 57 65 63 79 182 132 118 7 20 44 144
2024/20254.910 602 94 75 78 84 350 861 490 861 739 292 384
2025/202612.840 1.026 1.134 972 1.997 967 367 1.063 944 3.794 576 0 0
Totale 20.875